Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. has announced a new cash management strategy involving the use of temporarily idle proceeds to purchase principal guaranteed investment products with high security and good liquidity. This move aims to improve the efficiency of fund utilization without affecting the company’s ongoing investment plans, and it has been approved by the Board of Directors, with a validity of 12 months.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, focusing on the development and commercialization of innovative therapies, particularly in the field of immuno-oncology.
Average Trading Volume: 6,534,543
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.74B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.